A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. - Wikidata - wikimedia - TriplyDB

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.

http://www.wikidata.org/entity/Q40577742

about

Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?Hypoxia and fungal pathogenesis: to air or not to air?Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Efficacy and safety of amphotericin B lipid-based formulations-A systematic review and meta-analysis.Clinical Translation of Nanomedicine.Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia.Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients Therapy of murine pulmonary aspergillosis with antibody-alliinase conjugates and alliin.Susceptibility breakpoints for amphotericin B and Aspergillus species in an in vitro pharmacokinetic-pharmacodynamic model simulating free-drug concentrations in human serum.Aspergillus infections in transplant recipients.Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection.Fungal infections in transplant and oncology patients.Nanopharmaceuticals (part 1): products on the market.Canadian clinical practice guidelines for invasive candidiasis in adults.Treatment options in Invasive Aspergillosis.Antifungal agents for the treatment of systemic fungal infections in children.Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Clinical hepatotoxicity associated with antifungal agents.Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model Antifungal pharmacotherapy for invasive mould infections.The lipid formulations of amphotericin B.How to treat fungal infections in ICU patients.Invasive aspergillosis in patients with hematologic malignancies.Management of infectious complications in the hematopoietic stem cell transplant recipient.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders.Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications.Clinical Features and Prognosis of Invasive Pulmonary Aspergillosis in Korean Children with Hematologic/Oncologic Diseases Recent advances in antifungal pharmacotherapy for invasive fungal infections.New developments in antifungal strategy.Liposomal amphotericin B: clinical experience and perspectives.Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions.Amphotericin B-associated hyperbilirubinemia: case report and review of the literature.Fungal pneumonia due to molds in patients with hematological malignancies.Primary invasive aspergillosis of the digestive tract: report of two cases and review of the literature

P2860

Q24193811-69644775-83B9-44C7-B673-C575A7870F6B Q24239978-0B3524FE-898C-4EB6-A144-BE9BB70A8C2E Q26740363-88E43C1D-379E-41A4-A161-43794F871AFA Q27023320-8E9AA821-679E-433A-9D41-853366D8B638 Q27025299-9901B564-BA4D-45BF-A2DC-960BB9C589F4 Q30240770-F7C70DAF-BE1C-4EE8-8491-3ABD4A08BA72 Q30355939-365F4290-4B4E-4E76-808C-2E708333B112 Q30887348-9A105F90-461D-43B2-9652-3F44926F82E7 Q31161843-8ACFBF0A-1D56-4876-A554-579339F0D2A6 Q33371455-2A58381F-DE39-4BA7-9B66-1EEF5D77C59E Q33573788-0051E1F9-AE20-4C99-870C-64FEB568BFBC Q33613647-41E9622C-8B79-4D86-9475-199C50EB606D Q33622932-F9E825D4-D36E-40E3-B536-9DB7CE8D94B2 Q33719294-B87F5A8C-BC0F-48D3-8645-61E953FC0A49 Q33722067-F1FABDAB-F0C0-4C31-93E5-760CC019CB69 Q33876645-714EC68B-1A83-46FF-8792-429980C76B73 Q33896940-B027D45B-4D9C-44B5-B0CB-88D2F3B59475 Q34230175-07AEF673-2CD5-4646-8C56-F9DAEC865E29 Q34237335-01BF37E3-A8EB-4D0A-A4CC-F9FB92ABAE53 Q34357504-58C59FEE-7593-4E51-8D9B-81530528FD4C Q34437094-776265C7-C538-4AD9-A861-9678ADA16631 Q34532546-E00F87C1-C433-441A-9E4D-806D7D5D3AB1 Q34546811-8F098FC3-A356-4EAE-84F2-002CCEBF386F Q34680675-B7743423-37CB-4737-9956-9539D302FABE Q35058091-299DA43D-6B91-4B13-AA80-5AF9FE450E07 Q35183734-A9DEC2A2-FD7C-4034-9152-84AEFA97FD23 Q35568846-46F33242-2244-4D31-9C71-0FBF7B5E6F50 Q35616161-81022440-0CDF-477B-A7A6-5C3B299C3511 Q35675979-08E001E6-7A94-4672-A4AE-2E1893194065 Q35746695-2F8E59D4-E6EC-432E-A41A-408510664205 Q35782575-13D9C24E-0960-4E1E-A2CF-D2E1BFDB3E7F Q35889014-B694DD69-7005-422E-A016-F5F81827C780 Q35905124-66FA4C35-ED78-4FB6-91CE-1C83AACDBD41 Q35917383-09B2B27D-4F94-4E64-ABA5-5D1A52300E24 Q35917388-BCFBB13D-C8F3-4732-81A6-EFEE6394833C Q36140647-83F1B7CB-0667-4F88-8436-E6C637AABF73 Q36326220-CEB16F6C-B415-42C3-961A-14E568D4CEE2 Q36551571-9F6F636F-A46E-40D7-A862-CD9728609133 Q36616182-0CF58639-33B8-4144-88DA-ECDCEE4560EE Q36688610-CF90383B-C188-4C00-A2B4-171C1313E33C

P2860

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.

http://www.wikidata.org/entity/Q40577742

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

A double-blind, randomized, co ...... in immunocompromised patients.

@en

type

label

A double-blind, randomized, co ...... in immunocompromised patients.

@en

prefLabel

A double-blind, randomized, co ...... in immunocompromised patients.

@en

P1433

Q40577742-E0B3537C-52B4-40C0-91AF-17AB6BB6F656

P1476

Q40577742-66ED418E-5620-4052-95EE-4D684893F670

P2093

Q40577742-1D94F17A-157B-4FE1-9740-663BD63BB51B

Q40577742-2B90F16E-719C-4957-A7B7-8A96AE01E3B4

Q40577742-2D28E6D7-713A-411C-9B06-D45639860A7E

Q40577742-52EA7EFE-3627-4FB5-9F22-8EF9F0DAE13B

Q40577742-739D9B7C-57B9-4403-9C18-16793755DEC1

Q40577742-7FFFDABE-FBF6-40FD-B419-242AC18FC9E0

Q40577742-A124D8CC-E56A-4CD5-8579-1391C787CDEF

Q40577742-A2DED0EC-46E2-454D-B22B-954C3E904756

Q40577742-FAE385B6-23A9-497E-B7C5-B3215828814B

Q40577742-FC88132D-4616-4754-B373-DE169542709E

P2860

Q40577742-385E5C93-BBF4-42D2-8A4B-B4C79A176D4D

Q40577742-41D19000-73AE-4D7E-BDBE-2189057F0AD7

Q40577742-68C292D3-4344-416D-9EB4-E6A3D5D2EAE7

Q40577742-70F6EF61-69D0-46CE-B11D-B13B1EFEFA91

Q40577742-784EEB1B-1F41-4251-93B5-12AE6FD98E2B

Q40577742-87754CFB-22B8-4EB6-8270-582547393426

Q40577742-8CEDFA22-E3C8-42DD-B3C7-E48E89D9D2D6

Q40577742-90F502F1-9633-4A7C-B24F-AA54F60FABB3

Q40577742-945AD8D2-EF0B-4B0B-A395-FA64327835A1

Q40577742-A2CAD9B9-A3F9-4BF4-A198-32BA394052F7

P304

Q40577742-D3A99CA8-751D-4246-9B9D-BB1F2F30CB23

P31

Q40577742-5B104B76-DD86-4792-B2A8-EF8EE5C924AE

P356

Q40577742-D3F1C8D9-F5A3-424B-A4DF-6DFFC71FE1D0

P407

Q40577742-5E11C988-BAD0-4C6D-82C4-4FDDECCB1E12

P433

Q40577742-FBB092CC-BCD1-4EAC-8B5A-F1C51BC1FB18

P478

Q40577742-547B4622-B5A6-402D-A7E3-D8257C4561F1

P577

Q40577742-76E3813B-3FB1-422C-966B-2C1C2A20E497

P5875

Q40577742-DAF8AC50-C9C5-472D-B65D-DACC73FA9355

P698

Q40577742-9F816845-6F84-46DA-B91D-CBF87CCEF97F

P921

Q40577742-4361CFD7-A5A6-4823-8846-124AD9C5C585

P356

P1433

Clinical Infectious Diseases

P1476

A double-blind, randomized, co ...... in immunocompromised patients.

@en

P2093

Jo-Anne van Burik

http://www.w3.org/2001/XMLSchema#string

John R Wingard

http://www.w3.org/2001/XMLSchema#string

Larry Pietrelli

http://www.w3.org/2001/XMLSchema#string

Marc Gurwith

http://www.w3.org/2001/XMLSchema#string

Mary H White

http://www.w3.org/2001/XMLSchema#string

Michel Laverdiere

http://www.w3.org/2001/XMLSchema#string

Pranatharthi Chandrasekar

http://www.w3.org/2001/XMLSchema#string

Raleigh Bowden

http://www.w3.org/2001/XMLSchema#string

Sharon Safrin

http://www.w3.org/2001/XMLSchema#string

Xin Li

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment of invasive fungal infections with amphotericin B colloidal dispersion in bone marrow transplant recipients

Antifungal agents used for deep-seated mycotic infections.

Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis.

Efficacy and safety of amphotericin B colloidal dispersion compared with those of amphotericin B deoxycholate suspension for treatment of disseminated murine cryptococcosis.

Drug-induced nephrotoxicity. Aetiology, clinical features and management.

Therapeutic outcome in invasive aspergillosis.

Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion.

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group.

Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant.

The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses.

P304

359-366

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/341401

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

2002-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11236319

http://www.w3.org/2001/XMLSchema#string

P698

12145716

http://www.w3.org/2001/XMLSchema#string

P921